Noble Financial Has Positive Outlook of TNXP FY2025 Earnings

Key Points

• Noble Financial raised its FY2025 EPS estimate for Tonix to ($13.84) from ($14.95) and projects FY2026 EPS of ($8.01), with quarterly EPS forecasts from ($3.65) in Q4 2025 to ($1.28) in Q4 2026.
• TNXP shares opened at $17.09 and were trading down about 6.2% with a market cap of $201.3M; the company reported last quarter EPS of ($3.59) (in line with estimates) and revenue of $3.29M (above expectations), but remains deeply unprofitable with a negative ROE of 55.19% and a net margin of -963.39%.
• Analyst coverage is mixed (two Buys, one Sell) producing an average Hold rating and a consensus target of $70.00, and institutional investors own about 82.26% of the stock.

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) - Investment analysts at Noble Financial raised their FY2025 earnings per share estimates for shares of Tonix Pharmaceuticals in a research report issued to clients and investors on Wednesday, December 17th. Noble Financial analyst R. Leboyer now anticipates that the company will post earnings per share of ($13.84) for the year, up from their previous forecast of ($14.95). The consensus estimate for Tonix Pharmaceuticals' current full-year earnings is ($1,762.50) per share. Noble Financial also issued estimates for Tonix Pharmaceuticals' Q4 2025 earnings at ($3.65) EPS, Q1 2026 earnings at ($2.60) EPS, Q2 2026 earnings at ($2.25) EPS, Q3 2026 earnings at ($1.88) EPS, Q4 2026 earnings at ($1.28) EPS and FY2026 earnings at ($8.01) EPS.

Several other equities research analysts also recently commented on TNXP. Wall Street Zen raised Tonix Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday, November 15th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Tonix Pharmaceuticals in a research note on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $70.00.

Tonix Pharmaceuticals Trading Down 6.2%

Shares of TNXP opened at $17.09 on Monday. The stock has a market capitalization of $201.32 million, a price-to-earnings ratio of -0.85 and a beta of 1.82. Tonix Pharmaceuticals has a 12 month low of $6.76 and a 12 month high of $69.99. The firm has a fifty day simple moving average of $17.88 and a 200 day simple moving average of $29.31.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last posted its quarterly earnings data on Monday, November 10th. The company reported ($3.59) earnings per share for the quarter, hitting the consensus estimate of ($3.59). Tonix Pharmaceuticals had a negative return on equity of 55.19% and a negative net margin of 963.39%.The company had revenue of $3.29 million during the quarter, compared to analysts' expectations of $2.30 million.

Institutional Trading of Tonix Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the stock. Legal & General Group Plc acquired a new stake in Tonix Pharmaceuticals in the second quarter valued at $25,000. Ameritas Investment Partners Inc. bought a new stake in shares of Tonix Pharmaceuticals in the 2nd quarter valued at about $28,000. Russell Investments Group Ltd. acquired a new stake in shares of Tonix Pharmaceuticals in the third quarter valued at about $29,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Tonix Pharmaceuticals in the second quarter valued at about $62,000. Finally, BNP Paribas Financial Markets bought a new position in shares of Tonix Pharmaceuticals during the second quarter worth about $65,000. Institutional investors and hedge funds own 82.26% of the company's stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company's pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.

Among Tonix's lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.